This is a test
- 504 pages
- English
- PDF
- Available on iOS & Android
eBook - PDF
Pharmaceutical Public Policy
Book details
Table of contents
Citations
About This Book
As the most common health-care intervention, prescription drug use shares the most important characteristics of the health-care system in the United States. When everything works well, it makes possible breathtakingly successful applications of science to the prevention and cure of human suffering. But everything doesn't always work well. Pharmaceu
Frequently asked questions
At the moment all of our mobile-responsive ePub books are available to download via the app. Most of our PDFs are also available to download and we're working on making the final remaining ones downloadable now. Learn more here.
Both plans give you full access to the library and all of Perlegoâs features. The only differences are the price and subscription period: With the annual plan youâll save around 30% compared to 12 months on the monthly plan.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, weâve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes, you can access Pharmaceutical Public Policy by Thomas R. Fulda, Alan Lyles, Albert I Wertheimer in PDF and/or ePUB format, as well as other popular books in Business & Operations. We have over one million books available in our catalogue for you to explore.
Table of contents
- Front Cover
- Contents
- Foreword
- Preface
- Editors
- Contributors
- Chapter 1: Policy Process
- Chapter 2: Federal Legislative Process
- Chapter 3: Role of Federal Regulations and How They Are Developed
- Chapter 4: Access, Quality, and Cost
- Chapter 5: Why Is Medication Use Less than Appropriate?
- Chapter 6: Medication Adherence and Health Policy
- Chapter 7: Good Governance and Corruption in the Pharmaceutical System
- Chapter 8: U. S. Food and Drug Administration
- Chapter 9: Risk Minimization: A New Regulatory Challenge Directive
- Chapter 10: Drug Shortages
- Chapter 11: Drug Reimportation into the United States
- Chapter 12: Competition between Brand-Name and Generic Drugs
- Chapter 13: Structure and Dynamics of the Pharmaceutical Industry
- Chapter 14: Health Policy and Economic Issues in Biotechnology and Personalized Medicine
- Chapter 15: Pharmaceutical Promotion in the United States
- Chapter 16: Health Technology Assessment
- Chapter 17: Pharmacoeconomics as a Response to Market Failure: An International Perspective
- Chapter 18: Market for Pharmaceuticals
- Chapter 19: Managed Care Pharmacy and Pharmacy Benefit Management
- Chapter 20: Drug Insurance Design and Management
- Chapter 21: Electronic Information Technology
- Chapter 22: Assessing Medicare Part D after 10 Years
- Chapter 23: Medicaid
- Chapter 24: Medication Therapy Management Services
- Chapter 25: The Affordable Care Act: Potential Impacts on Pharmaceutical Markets
- Chapter 26: Role of Government as Regulator, Payer, and Provider of Care
- Chapter 27: Department of Veterans Affairs Pharmacy Programs
- Chapter 28: Public Health Service
- Back Cover